Evotec signs up for a 5-year discovery deal with Bayer focused on chronic kidney disease
Four years after Evotec first signed on to collaborate with Bayer on new therapies for endometriosis, the partners have decided to add a new discovery effort focused on chronic kidney disease.
Under the agreement, investigators at both companies will get a chance to contribute targets to the research effort. Evotec gets a guarantee of at least 14 million euros over the 5-year stretch of the collaboration. And there’s a chance to earn another $300 million euros in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
